Medical Costs of Adverse Events Associated with Patients Diagnosed with Chronic Myeloid Leukemia.

Tyrosine kinase inhibitors (eg, imatinib) have revolutionized the treatment of chronic myeloid leukemia (CML). However, new therapies developed to treat imatinib-resistant CML may be associated with undesirable side effects. The purpose of this analysis was to quantify the medical costs for significant adverse events (AE) associated with patients diagnosed with CML. De-identified medical and pharmacy claims data from 5 million individuals covered by 31 large U.S. corporations between 1/98 and 1/05 were used. CML patients were identified as patients